Guardant Health EBITDA 2017-2022 | GH
Guardant Health ebitda from 2017 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Guardant Health Annual EBITDA
(Millions of US $) |
| 2021 |
$-373 |
| 2020 |
$-230 |
| 2019 |
$-73 |
| 2018 |
$-86 |
| 2017 |
$-71 |
| 2016 |
$-40 |
Guardant Health Quarterly EBITDA
(Millions of US $) |
| 2022-03-31 |
$-113 |
| 2021-12-31 |
$-88 |
| 2021-09-30 |
$-98 |
| 2021-06-30 |
$-88 |
| 2021-03-31 |
$-99 |
| 2020-12-31 |
$-79 |
| 2020-09-30 |
$-69 |
| 2020-06-30 |
$-50 |
| 2020-03-31 |
$-31 |
| 2019-12-31 |
$-23 |
| 2019-09-30 |
$-17 |
| 2019-06-30 |
$-13 |
| 2019-03-31 |
$-21 |
| 2018-12-31 |
$-26 |
| 2018-09-30 |
$-22 |
| 2018-06-30 |
$-21 |
| 2018-03-31 |
$-17 |
| 2017-12-31 |
|
| 2017-09-30 |
$-29 |
| 2016-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.799B |
$0.374B |
|
Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.
|
